BR112013009701A2 - regimes de dosagem para o tratamento de doença vascular ocular - Google Patents
regimes de dosagem para o tratamento de doença vascular ocularInfo
- Publication number
- BR112013009701A2 BR112013009701A2 BR112013009701A BR112013009701A BR112013009701A2 BR 112013009701 A2 BR112013009701 A2 BR 112013009701A2 BR 112013009701 A BR112013009701 A BR 112013009701A BR 112013009701 A BR112013009701 A BR 112013009701A BR 112013009701 A2 BR112013009701 A2 BR 112013009701A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- vascular disease
- dosage regimens
- eye vascular
- eye
- Prior art date
Links
- 208000019553 vascular disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40721810P | 2010-10-27 | 2010-10-27 | |
| PCT/EP2011/068682 WO2012055884A1 (en) | 2010-10-27 | 2011-10-25 | Dosing regimes for the treatment of ocular vascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013009701A2 true BR112013009701A2 (pt) | 2016-07-19 |
Family
ID=44913251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013009701A BR112013009701A2 (pt) | 2010-10-27 | 2011-10-25 | regimes de dosagem para o tratamento de doença vascular ocular |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130197016A1 (enExample) |
| EP (1) | EP2632458B1 (enExample) |
| JP (1) | JP5934229B2 (enExample) |
| KR (1) | KR20140008303A (enExample) |
| CN (1) | CN103167873A (enExample) |
| AU (1) | AU2011322597B2 (enExample) |
| BR (1) | BR112013009701A2 (enExample) |
| CA (1) | CA2814439A1 (enExample) |
| EA (1) | EA022873B1 (enExample) |
| ES (1) | ES2547145T3 (enExample) |
| MX (1) | MX2013004782A (enExample) |
| WO (1) | WO2012055884A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| US9353122B2 (en) * | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US10174006B2 (en) | 2013-06-06 | 2019-01-08 | Novartis Ag | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease |
| EP3570093B1 (en) | 2013-11-15 | 2021-09-15 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
| JPWO2015147204A1 (ja) * | 2014-03-27 | 2017-04-13 | 国立大学法人京都大学 | 血管新生増殖因子を阻害する医薬組成物 |
| CN107206119B (zh) | 2014-12-09 | 2021-01-29 | 实体科学公司 | 具有生物相容性层的医疗设备涂层 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| WO2021067823A2 (en) * | 2019-10-05 | 2021-04-08 | The Schepens Eye Research Institute, Inc. | A new treatment for meibomian gland dysfunction |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1382604B1 (en) | 2001-04-27 | 2005-12-28 | Kirin Beer Kabushiki Kaisha | Quinoline derivative having azolyl group and quinazoline derivative |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| EP2380572A1 (en) | 2005-11-29 | 2011-10-26 | Glaxosmithkline LLC | Cancer treatment method |
| CA2666709A1 (en) * | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
-
2011
- 2011-10-25 KR KR1020137010744A patent/KR20140008303A/ko not_active Withdrawn
- 2011-10-25 CN CN2011800496321A patent/CN103167873A/zh active Pending
- 2011-10-25 EA EA201390618A patent/EA022873B1/ru not_active IP Right Cessation
- 2011-10-25 AU AU2011322597A patent/AU2011322597B2/en not_active Ceased
- 2011-10-25 ES ES11779606.0T patent/ES2547145T3/es active Active
- 2011-10-25 WO PCT/EP2011/068682 patent/WO2012055884A1/en not_active Ceased
- 2011-10-25 CA CA2814439A patent/CA2814439A1/en not_active Abandoned
- 2011-10-25 US US13/878,678 patent/US20130197016A1/en not_active Abandoned
- 2011-10-25 MX MX2013004782A patent/MX2013004782A/es not_active Application Discontinuation
- 2011-10-25 JP JP2013535408A patent/JP5934229B2/ja not_active Expired - Fee Related
- 2011-10-25 EP EP11779606.0A patent/EP2632458B1/en not_active Not-in-force
- 2011-10-25 BR BR112013009701A patent/BR112013009701A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2632458A1 (en) | 2013-09-04 |
| JP2013540791A (ja) | 2013-11-07 |
| US20130197016A1 (en) | 2013-08-01 |
| JP5934229B2 (ja) | 2016-06-15 |
| AU2011322597A1 (en) | 2013-05-02 |
| EA022873B1 (ru) | 2016-03-31 |
| AU2011322597B2 (en) | 2015-09-10 |
| EP2632458B1 (en) | 2015-08-12 |
| MX2013004782A (es) | 2013-06-03 |
| WO2012055884A1 (en) | 2012-05-03 |
| CN103167873A (zh) | 2013-06-19 |
| ES2547145T3 (es) | 2015-10-02 |
| KR20140008303A (ko) | 2014-01-21 |
| CA2814439A1 (en) | 2012-05-03 |
| EA201390618A1 (ru) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260585B (en) | Compositions and methods for treating retinal diseases | |
| EP2846847A4 (en) | BIOKOMPATIBLE HYDROGEL TREATMENTS FOR NETWORK SKIN REMOVAL | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| CL2015000061A1 (es) | Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares | |
| IL233313A0 (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
| CO6940374A2 (es) | Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas | |
| EP2683382A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY | |
| HUE039864T2 (hu) | Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére | |
| HUE053565T2 (hu) | Adagolási rendek Pompe betegség kezelésére | |
| EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
| CO6930321A2 (es) | Curación de tejidos | |
| EP2731534A4 (en) | Retinal laser surgery | |
| IL230957A0 (en) | Pharmacy methods and preparations for the treatment of an eye disease in a patient | |
| HRP20181378T1 (hr) | Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom | |
| IL229017B (en) | Oxidative retinal diseases | |
| PT2877184T (pt) | Composições e tratamento para doenças e distúrbios oculares | |
| SG11201407162SA (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| PL2582366T3 (pl) | Kombinacja farmaceutyczna do leczenia bólu | |
| DK2747763T3 (da) | (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser | |
| EP2623494A4 (en) | MEDICINE FOR THE TREATMENT OF EYE DISEASES | |
| HRP20180575T1 (hr) | Cervikalni jastuk za liječenje bolesti vratne kralježnice | |
| IL230960A0 (en) | A device for the treatment of eye disease | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| PL2718434T3 (pl) | Kompozycje i sposoby leczenia choroby trzewnej | |
| IL231922A0 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |